Page last updated: 2024-10-16

beta-alanine and Blood Loss, Surgical

beta-alanine has been researched along with Blood Loss, Surgical in 9 studies

Blood Loss, Surgical: Loss of blood during a surgical procedure.

Research Excerpts

ExcerptRelevanceReference
"Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required."9.16Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012)
"Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required."5.16Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012)
" We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban."4.89The novel anticoagulants: the surgeons' prospective. ( Martin, EN; Money, SR; Shamoun, FE, 2013)
"Prospective, double-blind studies in orthopaedic patients have been conducted using the direct thrombin inhibitor dabigatran etexilate (hereafter referred to as dabigatran), with two doses investigated and approved for adults (220 mg and 150 mg once daily) to prevent venous thromboembolism (VTE)."4.88Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. ( Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N, 2012)
"To reverse the anticoagulant effects of warfarin in patients who are bleeding or need surgery, exogenous vitamin K (phytonadione) may be used in combination with another, shorter-acting intervention, such as fresh frozen plasma (FFP), prothrombin complex concentrate (PCC), recombinant factor VIIa, or activated PCC (aPCC)."3.79Pharmacologic interventions for reversing the effects of oral anticoagulants. ( Kalus, JS, 2013)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Llau, JV1
Ferrandis, R1
Castillo, J1
de Andrés, J1
Gomar, C1
Gómez-Luque, A1
Hidalgo, F1
Torres, LM1
McKenzie, JL1
Douglas, G1
Bazargan, A1
Kalus, JS1
John, A1
Michel, MS1
Tran, H1
Joseph, J1
Young, L1
McRae, S1
Curnow, J1
Nandurkar, H1
Wood, P1
McLintock, C1
Dahl, OE1
Kurth, AA1
Rosencher, N1
Noack, H1
Clemens, A1
Eriksson, BI1
Healey, JS1
Eikelboom, J1
Douketis, J1
Wallentin, L1
Oldgren, J1
Yang, S1
Themeles, E1
Heidbuchel, H1
Heidbuchle, H1
Avezum, A1
Reilly, P1
Connolly, SJ1
Yusuf, S1
Ezekowitz, M1
Turpie, AG1
Kreutz, R1
Llau, J1
Norrving, B1
Haas, S1
Shamoun, FE1
Martin, EN1
Money, SR1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Observational Study of the Direct Oral Anticoagulants Periprocedural Management[NCT03182218]1,100 participants (Actual)Observational2015-02-28Completed
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants[NCT02185027]1,166 participants (Actual)Observational2013-06-30Completed
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600]Phase 318,113 participants (Actual)Interventional2005-12-31Completed
Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386]Phase 360 participants (Actual)Interventional2017-05-03Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Abnormal Liver Function Test

Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months

Interventionparticipants (Number)
Dabigatran 110 mg11
Dabigatran 150 mg14
Warfarin21

Yearly Event Rate for Composite Endpoint of Stroke/SEE

Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg1.54
Dabigatran 150 mg1.11
Warfarin1.71

Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death

Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.85
Dabigatran 150 mg4.32
Warfarin5.20

Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death

Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.26
Dabigatran 150 mg3.68
Warfarin4.35

Bleeding Events (Major and Minor)

"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage) (Number)
Major bleedsMinor bleeds
Dabigatran 110 mg2.9913.16
Dabigatran 150 mg3.5514.85
Warfarin3.8116.37

Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)

Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage)] (Number)
intracerebral hemorrhageintracranial hemorrhage (ICH)
Dabigatran 110 mg0.120.23
Dabigatran 150 mg0.100.32
Warfarin0.380.76

Reviews

5 reviews available for beta-alanine and Blood Loss, Surgical

ArticleYear
[Recommendations on use of direct oral anticoagulants in the perioperative period].
    Medicina clinica, 2012, Volume: 139 Suppl 2

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran

2012
Perioperative management of anticoagulation in elective surgery.
    ANZ journal of surgery, 2013, Volume: 83, Issue:11

    Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Cardiovascular Di

2013
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
    International orthopaedics, 2012, Volume: 36, Issue:4

    Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine;

2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2012
The novel anticoagulants: the surgeons' prospective.
    Surgery, 2013, Volume: 153, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Tr

2013

Trials

1 trial available for beta-alanine and Blood Loss, Surgical

ArticleYear
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Circulation, 2012, Jul-17, Volume: 126, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I

2012

Other Studies

3 other studies available for beta-alanine and Blood Loss, Surgical

ArticleYear
Pharmacologic interventions for reversing the effects of oral anticoagulants.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, May-15, Volume: 70, Issue:10 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-A

2013
[Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
    Der Urologe. Ausg. A, 2014, Volume: 53, Issue:6

    Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran

2014
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
    Internal medicine journal, 2014, Volume: 44, Issue:6

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu

2014